Sichuan clarify the management rules of the R & D risk sharing fund of Chinese medicine

Content source: China Traditional Chinese Medicine Reporter: Fang Bi Tao

Bleak

Recently, the Sichuan Provincial Administration of Traditional Chinese Medicine and the Provincial Department of Finance jointly issued the "Implementation Rules for the Management of the R & D Risk Sharing Fund in Sichuan Province" to clarify the applicable objects, scope of sharing and standards of risk sharing funds (hereinafter referred to as "dangerous insurance funds") content. Inspiring and protecting the enthusiasm, initiative and creativity of the province's Chinese medicine science and technology innovation enterprises, reducing the risk of scientific research in Chinese medicine in enterprises.

According to the "Detailed Rules", the insurance fund is mainly for enterprises that expand the innovation of traditional Chinese medicine scientific and technological innovation. The applicable objects include the establishment, registration, and registration in the administrative area of ​​Sichuan Province. Enterprise; sharing scope includes research, development and technological innovation, technical application, and technological achievements of Chinese medicine innovation drugs, traditional Chinese medicine improved new drugs, ancient classic Chinese medicine compound preparations.

The "Detailed Rules" clearly gives risk sharing according to 30%of the loss of 30%of the loss of actual scientific research input, and the actual investment of a single project shall not be less than 1 million yuan. The sharing limit of the insurance fund is the category of traditional Chinese medicine raw materials. The maximum sharing limit of a single project is 1 million yuan; the category of traditional Chinese medicine drinks, the second type of traditional Chinese medicine medical equipment, the maximum sharing limit of a single item is 3 million yuan; the new drug improvement of traditional Chinese medicine, the ancient classic famous prescriptions Chinese medicine compound preparations, secondary development of Chinese medicine after listing, and other categories. The maximum sharing limit of a single project is 5 million yuan; the category of Chinese medicine innovation medicines, the maximum sharing limit of a single project is 10 million yuan.

The "Detailed Rules" requires that the undertaking unit of the R & D project of the risk sharing shall be submitted to the Provincial Administration of Traditional Chinese Medicine and submitted to the filing materials.

Edit: Dong Juntong

- END -